Volume 1, # 2/3 - June/July, 1995
Table of Contents
|
| STATE-OF-THE-ART MANAGEMENT OF CANCER |
| CANCERS OF THE DIGESTIVE SYSTEM - PART II |
| Screening, Diagnosis and Monitoring |
34 |
| Esophageal Cancer |
34 |
| Stomach Cancer |
34 |
| Live Cancer |
35 |
| Pancreatic Cancer |
36 |
| Colorectal Cancer |
37 |
| Occult blood |
37 |
| Flexible sigmoidoscopy |
37 |
| Tumor markers |
38 |
| Genetic testing |
38 |
| Screening of high risk groups |
38 |
| Radioimmunoscintigraphy |
39 |
| Gallbladder Cancer |
39 |
| Cancer of the Small Intestine |
39 |
| Anal Cancer |
40 |
| Current Therapy |
40 |
| Esophageal Cancer |
40 |
| Stomach Cancer |
41 |
| Primary Hepatocellular Carcinoma (HCC) |
41 |
| Metastatic Neoplasms of the Liver |
42 |
| Regional therapy |
43 |
| Chemoembolization |
44 |
| Radiotherapy |
44 |
| Liver transplants |
45 |
| Other therapies |
45 |
| Neoplasms of the Extrahepatic Bile Ducts |
45 |
| Pancreatic Cancer |
46 |
| Colorectal Cancer |
47 |
| Gallbladder Cancer |
49 |
| Cancer of the Small Intestine |
49 |
| Anal Cancer |
50 |
| New Drugs and Allied Therapies in Development |
50 |
| Gene Therapy/Vaccines/Immunomodulating Agents/Monoclonal Antibodies |
51 |
| Aphton |
51 |
| Biomira |
51 |
| Bristol-Myers Squibb |
51 |
| Canji |
51 |
| Centocor |
52 |
| Corixa |
52 |
| Cytel |
52 |
| Genetics Institute |
52 |
| ImClone |
52 |
| Immune Response |
53 |
| Immunomedics |
53 |
| ImmunoTherapeutics |
53 |
| Jenner Technologies |
53 |
| NeoRx |
53 |
| Seragen |
53 |
| Somatix Therapy |
53 |
| StressGen Biotechnologies |
53 |
| Therion Biologics |
54 |
| University of Alabama |
54 |
| Vical |
54 |
| The Wistar Institute |
54 |
| Thymidylate Synthase Inhibitors |
54 |
| ZD1694 |
55 |
| AG337 and AG331 |
55 |
| UFT |
55 |
| Topoisomerase I Inhibitors |
56 |
| CPT-11 |
56 |
| Drug Delivery |
56 |
| Liposomes |
56 |
| Matrix Pharmaceutical |
56 |
| Sparta Pharmaceuticals |
56 |
| Photodynamic Therapy (PDT) |
56 |
| MEETING COVERAGE |
RADIOIMMUNOSCINTIGRAPHY IN CANCER DIAGNOSIS
A Report From the Tenth International Conference on Monoclonal Antibody Immunoconjugates for Cancer
March 9-11, 1995 - San Diego, CA |
| Challenges Facing MAb-Based Radioscintigraphy |
65 |
| Radioisotope Choice |
65 |
| Development of MAbs for in vivo Imaging Applications |
65 |
| Targeting growth factors or oncogenes |
65 |
| MAb fragments |
65 |
| MAb dosing requirements |
67 |
| SPECT imaging |
67 |
| Selected Diagnostic Applications |
67 |
| Colorectal Cancer |
67 |
| Pancreatic Cancer |
68 |
| Hodgkin's Lymphoma |
68 |
| Clinical Challenges to Radioimmunoscintigraphy |
69 |
| Increasing Scintigraphic Contrast |
70 |
| Pretargeting |
69 |
| Enhancing Tumor Access |
70 |
| Reducing Antibody Immunogenicity |
71 |
| Human MAbs |
71 |
| Assessing True Benefit of Radioimmunoscintigraphy |
71 |
| Intraoperative Use of Radioimmunoconjugates |
72 |
| Radioimmunoguided Surgery (RIGS) |
72 |
| Beta-ray Systems |
72 |
HIGHLIGHTS OF DIGESTIVE DISEASE WEEK
San Diego, CA - May 14-17, 1995 |
| Gastric Malt Lymphoma and H.Pylori |
73 |
| Esophageal Cancer Treatments |
73 |
| Multimodal Therapy |
73 |
| Stents |
73 |
| Microwave Coagulation Therapy (MCT) in Liver Cancer |
73 |
| MECHANISMS IN MALIGNANCY |
DRUG RESISTANCE IN CANCER - PART I
|
| General Mechanisms of Drug Resistance |
74 |
| Decreased Drug Accumulation |
74 |
| Altered Drug Metabolism |
74 |
| Increased Repair of Drug-Induced Damage |
74 |
| Altered Gene Expression |
74 |
| In Vivo Drug Resistance Factors |
75 |
| Multidrug Resistance |
75 |
| Classic (P-Glycoprotein-Dependent) MDR |
75 |
| Other Gene Products in MDR |
75 |
| MDR Associated With Topoisomerase Alterations |
77 |
| Altered Expression of Drug-Metabolizing Enzymes and MDR |
78 |
| Apoptosis in MDR |
78 |
| Multiple Mechanisms in Drug-Resistant Tumors |
78 |
